BRPI0508992A - tratamento de pneumonia severa pela administração de tfpi - Google Patents

tratamento de pneumonia severa pela administração de tfpi

Info

Publication number
BRPI0508992A
BRPI0508992A BRPI0508992-1A BRPI0508992A BRPI0508992A BR PI0508992 A BRPI0508992 A BR PI0508992A BR PI0508992 A BRPI0508992 A BR PI0508992A BR PI0508992 A BRPI0508992 A BR PI0508992A
Authority
BR
Brazil
Prior art keywords
tfpi
administration
severe pneumonia
treatment
involve
Prior art date
Application number
BRPI0508992-1A
Other languages
English (en)
Inventor
Abla Creasy
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BRPI0508992A publication Critical patent/BRPI0508992A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

TRATAMENTO DE PNEUMONIA SEVERA PELA ADMINISTRAçãO DE TFPI Métodos para profilacticamente ou terapeuticamente tratar a pneumonia severa envolvem a administração do inibidor do pathway do fator do tecido (TFPI) ou um análogo de TFPI aos pacientes que sofrem ou no risco de desenvolver esta circunstância. Os métodos envolvem o uso por infusão intravenosa contínua de TFPI ou de um análogo de TFPI, em doses baixas evitar preferivelmente efeitos laterais adversos.
BRPI0508992-1A 2004-03-17 2005-03-17 tratamento de pneumonia severa pela administração de tfpi BRPI0508992A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468104P 2004-03-17 2004-03-17
PCT/US2005/009097 WO2005110059A2 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
BRPI0508992A true BRPI0508992A (pt) 2007-09-04

Family

ID=35394617

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508992-1A BRPI0508992A (pt) 2004-03-17 2005-03-17 tratamento de pneumonia severa pela administração de tfpi

Country Status (16)

Country Link
US (1) US20080286279A1 (pt)
EP (1) EP1729791A2 (pt)
JP (1) JP2007532486A (pt)
KR (1) KR20070007336A (pt)
CN (1) CN101426520A (pt)
AU (1) AU2005244249A1 (pt)
BR (1) BRPI0508992A (pt)
CA (1) CA2560103A1 (pt)
IL (1) IL178115A0 (pt)
MX (1) MXPA06010587A (pt)
NO (1) NO20064674L (pt)
RU (1) RU2006136267A (pt)
SG (1) SG150552A1 (pt)
TN (1) TNSN06295A1 (pt)
WO (1) WO2005110059A2 (pt)
ZA (1) ZA200608413B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN112587522B (zh) * 2020-12-03 2022-11-25 中国海洋大学 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) * 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
JPS6345230A (ja) * 1986-04-01 1988-02-26 Central Glass Co Ltd ブロモベンゾトリフルオリドの製造方法
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
USRE36476E (en) * 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5569644A (en) * 1995-05-18 1996-10-29 The Lubrizol Corporation Additive combinations for lubricants and functional fluids
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
EP1602667B1 (en) * 1995-06-07 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Aqueous formulation comprising TFPI and solubilizing agents
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6011136A (en) * 1995-11-21 2000-01-04 Novartis Ag Cyclopeptolides
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
EP0914830B1 (en) * 1996-03-25 2003-11-19 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Neovascularization inhibitor containing tissue factor pathway inhibitor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
BR9809292A (pt) * 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
IL142248A0 (en) * 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
WO2000077246A2 (en) * 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DE60217835D1 (en) * 2001-02-28 2007-03-15 John H Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
US6808927B2 (en) * 2001-04-04 2004-10-26 American Diagnostica, Inc. Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
CA2463655A1 (en) * 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US20020198138A1 (en) * 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
KR20070007336A (ko) 2007-01-15
AU2005244249A1 (en) 2005-11-24
MXPA06010587A (es) 2007-03-29
US20080286279A1 (en) 2008-11-20
ZA200608413B (en) 2008-06-25
JP2007532486A (ja) 2007-11-15
NO20064674L (no) 2006-11-29
EP1729791A2 (en) 2006-12-13
CN101426520A (zh) 2009-05-06
WO2005110059A2 (en) 2005-11-24
RU2006136267A (ru) 2008-04-27
IL178115A0 (en) 2008-03-20
SG150552A1 (en) 2009-03-30
CA2560103A1 (en) 2005-11-24
TNSN06295A1 (en) 2007-12-03
WO2005110059A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
BR0213292A (pt) tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BRPI0518861B8 (pt) compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR0308154A (pt) Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos
AR074214A1 (es) Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
BR112015012497A2 (pt) combinações farmacêuticas
BR0110913A (pt) Método de administrar um bisfosfonato
BRPI0508992A (pt) tratamento de pneumonia severa pela administração de tfpi
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.